VJHemOnc is the official media partner of the iwCAR-T Virtual Meeting!
This virtual workshop will cover trial updates and the latest thinking in CAR-T & cellular therapies from international leading experts in hematological oncology, featuring cutting edge presentations and live interactive panel discussions.
Register your place before the 29th of October!
https://register.gotowebinar.com/register/7327584602578872591
|
Program (all times in EST)
Thursday: October 29 2020
10:00 AM
Introduction & Meeting Objectives
John Gribben & David Maloney
10:05 – 11:25 AM
Session I: CAR-T in ALL
Chairs: Noelle Frey & Bijal Shah
- Novel CAR-T approaches for ALL: Rebecca Gardner
- CAR-T in adult ALL: Claire Roddie
- Allogeneic CAR-T in ALL: Bijal Shah
- Remission & Persistence: Shannon Maude
Panel discussion
11:25 – 12:45 PM
Session II: CAR-T in AML
Chairs: Saar Gill & John DiPersio
- Overview: Saar Gill
- CAR-T vs BiTEs for AML: John DiPersio
- NKG2D and anti-CD33 CAR-T: David Sallman
- CART-123 for AML: Elizabeth Budde
Panel discussion
12:45 – 14:00 PM
Session III: CAR-T in CLL
Chairs: John Gribben & David Porter
- Update CLL CAR-T trial landscape/JCAR: Tanya Siddiqi
- Long-term outcomes of anti-CD19 CAR-T in R/R CLL: David Porter
- CAR-T NK treatments in CLL: Katy Rezvani
- The role of CLL tumor cells in resistance to anti-CAR-T cell therapy: Joseph Melenhorst
Panel discussion
End of scientific session, Day 1
Friday: October 30 2020
10:00 AM
Introduction from co-chairs
John Gribben & David Maloney
10:00 – 11:15 AM
Session IV: CAR-T in Lymphoma
Chairs: Fred Locke & Caron Jacobsen
- CD19-CAR T-cells - trial updates: Jeremy Abramson
- CD30 update: Barbara Savoldo
- CD5 and CD7 CAR T-cells: Max Mamonkin
Panel discussion
11:15 – 12:35 PM
Session V: CAR-T in Myeloma
Chairs: Yi Lin & Noopur Raje
- BCMA CAR-T - ready for standard of care practice?: Nina Shah
- CAR-T trials in China: myeloma and CAR-T landscape in China: Jianxiang Wang
- BiTEs vs CARs: Hermann Einselle
- Beyond BCMA, other novel CAR-T targets and combinations: Eric Smith
Panel discussion
12:35 – 13:50 PM
Session V: Evolution of cellular therapies
Chairs: David Maloney & TBC
- Tmod CAR T-cells targeting loss of heterozygosity: William Go
- Repeat CAR-T infusions (ALL, NHL, CLL): Jordan Gauthier
- Informed design of engineered T-cell therapies for cancer: Stan Riddell
- Novel CAR platforms - allogeneic CAR-T, CAR-NK: Michael Hudecek
Panel discussion
Final meeting summary & conclusions
|
|
